More than Just Lines on a Map: Best Practices for U.S Bike Routes
UK Partnering Assets BIO 2015
1. UK BIO 2015 Attendee
Partnering Assets
Philadelphia, PA
12 June 2015
To connect with any of the companies
listed here, please contact
Kathryne.Kirk@mobile.ukti.gov.uk
3. 3
1. MGB-BP-3, oral for C. diff , Phase I
2. MGB-BP-3, IV for MRSA, VRE, and streptococcus , pre-
clinical
3. MGB-BP-3, topical, pre-clinical
4. Various discovery-stage compounds for Gram-negative
bacteria, anti-fungals, anti-virals, and anti-parasitics
Contact: Dr. Graham
Lumsden, CEO
1. Iclaprim, antibiotic against MDR, Gram-positive bacteria,
Phase III, expected commercialization as early as 2018
2. MTF-001, dihydrofolate reductase inhibitor (DHFRi)
against MDR bacteria, pre-clinical
Keywords: antibiotics, C. difficile , MRSA, Minor Groove
Binders, Gram-positive, Gram-negative, streptococcus, VRE,
anti-fungal, anti-viral, anti-parasitic, novel class
Description: Clinical-stage drug discovery and development
company focusing on Duchenne muscular dystrophy and C.
difficile Infection.
Contact: Dr. Andrew
Mulvaney, VP BD & Alliance
Management
Duchenne Muscular
Dystrophy and C. difficile
C. difficile and MRSA
Antibiotics
1. SMT19969, a first-in-class, oral selective antibiotic for C.
difficile Infection, currently in Phase II
2. Oral Utrophin Modulator Programme – disease modifying
therapies for Duchenne Muscular Dystrophy (DMD), Lead
Candidate SMT C1100 currently in Phase 1b
Keywords: antibiotics, orphan diseases, Duchenne
Muscular Dystrophy, Clostridium difficile
Name Assets
Keywords: antibiotics, multi-drug resistance, UTI,
respiratory infection, sepsis, STDs
Description: Discovery-stage company focused on
producing new, safe antibiotics effective against multidrug-
resistant bacteria.
About
MDR Antibiotics
1. Multiple unnamed novel compound series, in chemical
optimization
Contact: Dr. David Williams,
CEO
Contact: Dr. Miroslav Ravic,
Chief Executive Officer
MDR Antibiotics
Description: Clinical-stage company focused on the
development of a novel class of antibacterials based on
Minor Groove Binder (MGBs) compounds.
Keywords: antibiotics, infectious disease, multi-drug
resistant bacteria, MRSA, dihydrofolate reductase inhibitor
Description: Clinical-stage company focused on the
development of antibiotics to treat multi-drug resistant
bacteria.
4. 4
Description: Market-stage company looking for distribution
and marketing partners in yet-unmarketed areas.
Name About Assets
Chronic Constipation and
Kaposi's Sarcoma
Keywords: advanced HIV-related Kaposi's sarcoma,
constipation, fecal impaction, oncology, gastrointestinal
Contact: Dr. Romain
Lalandes, Business
Development & Licensing
Director
Description: Development-stage company focused on
products in the therapeutic areas of cough/cold, CNS,
oncology, and inflammation.
1. Laxido®, for constipation and fecal impaction, marketed
2. DaunoXome®, for advanced HIV-related Kaposi's
Sarcoma, marketed
1. V158866, for pain, spasticity, other neuro, Phase II
2. V81444, for Parkinson's disease, completed Phase II
3. AUY922, for solid and hematological cancers, completed
Phase II
4. V158411, for multiple cancers (Chk1 inhibitor), completed
pre-clinical
5. V85546, for COPD, MS and RA, completed Phase I
Multi-Disease
Keywords: pain, Parkinson's disease, oncology, cancer,
COPD, multiple sclerosis (MS), rheumatoid arthritis (RA)
Contact: Mr. Simon
Lawrence, VP Business
Development
5. 5
1. Biological Fluid Filtration Device, for capture of material
from biological fluids, such as tumor cells from urine, patent
pending
2. Phased Array High Intensity Focused Ultrasound (HIFU)
Technology, seeking investment or collaboration, for HIFU
procedures against pathogenic tissue.
Assets
1. Novel imaging agent for prostate and glioma tumor
detection
2. Novel protein tag for radiolabelling recombinant proteins
3. Amplified FRET-FLIM
4. High throughput leukemia initiating cell assay
5. Proximal kinase substrate identification method
1. CD55 antibodies
2. TACE antibody
4. MUC1 antibodies, P.O.C.
5. avβ6-binding peptides for
tumor targeting and imaging
6. CEA antibodies, Phase I
7. ADAM8, P.O.C.
4. Prognostic, for prostate
cancer
5. Validation, Integrin avβ6-
binding peptides for imaging
6. IBIS software (Tyrer-
Cuzick model), for breast
cancer risk assessment
1. Diagnostic, for pancreatic
cancer
2. Predictive, serum, for
Avastin treatment decision in
ovarian cancer
3. Diagnostic, MCM proteins
for lung cancer
Contact: Dr. Phil L'Huillier,
Executive Director, Business
Development
Description: Part of Cancer Research UK, CRT develops
and commercializes new discoveries in cancer research as
"the meeting point between academia and industry".
Contact: Dr. Phil L'Huillier,
Executive Director, Business
Development
Description: Part of Cancer Research UK, CRT develops
and commercializes new discoveries in cancer research as
"the meeting point between academia and industry".
Biological Therapeutics
Opportunities
8. Anti-avβ6 antibodies, lead
opt
9. S100A4 antibody
10. sIGF2R-Trap therapy
11. Jagged1 antibody
12. p53 TCR mimic antibody
13. CXCL12 antibody
1. Selective Aurora B/C
inhibitor, Phase I complete
2. CDK7 inhibitors, H2L
3. PAK inhibitors, pre-clin
4. LIMK1 and LIMK2
inhibitors, H2L / lead opt
5. Autotaxin inhibs, lead opt
6. Chk2 inhibitor, pre-clin
7. IKK alpha inhibs, lead opt
8. PRMT5 inhibitors, lead opt
9. FOXA1 inhibs, screening
10. Cancer Stem Cell
Consortium (Drug Discovery
Platform)
Enabling Technology
Opportunities
Keywords: imaging agents, prostate cancer, glioma, tumor
detection, radiolabelling, FRET-FILM, leukemia cell assay,
kinase substrate identification
Name About
Medical Devices
Opportunities
Keywords: biological fluid filtration, cancer diagnostics, high
intensity focused ultrasound, sonic ablation
Contact: Dr. Phil L'Huillier,
Executive Director, Business
Development
Keywords: antibodies, tumor targeting peptides, trap
therapy, angiogenesis, T cell receptors
Contact: Dr. Phil L'Huillier,
Executive Director, Business
Development
Description: Part of Cancer Research UK, CRT develops
and commercializes new discoveries in cancer research as
"the meeting point between academia and industry".
Keywords: diagnostics, screening, breast cancer risk,
imaging validation, ovarian cancer predictive, lung cancer,
pancreatic cancer, prostate cancer
Contact: Dr. Phil L'Huillier,
Executive Director, Business
Development
Description: Part of Cancer Research UK, CRT develops
and commercializes new discoveries in cancer research as
"the meeting point between academia and industry".
Description: Part of Cancer Research UK, CRT develops
and commercializes new discoveries in cancer research as
"the meeting point between academia and industry".
Biomarkers Opportunities
Small Molecules
Opportunities
Keywords: enzyme / checkpoint inhibitors, oncology targets,
cancer targets, pre-clinical, drug discovery platforms, stem
cells
6. 6
Keywords: small molecule inhibitors, enzyme inhibitors,
hypoxic tumors, colorectal cancer, mestastatic cancer, lung
cancer, hepatoma, head and neck tumors
Contact: Dr. Toby
Richardson, Associate
Director of BD
Description: A University of London and Royal Marsden
hospital affiliated research charity which ranks in the top four
institutes for cancer research worldwide.
Therapeutics Opportunities
Contact: Dr. Eddy Littler,
CEO
Description: Hybrid company with both CRO services and
an internal drug discovery pipeline focused on inflammatory
and oncologic disease.
1. MNK Inhibitors for outlicensing
Oncology
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Cancer Opportunities
1. TBK1/IKKε for COPD and
psoriasis, pre-clinical
2. G9a for oncology, pre-
clinical
3. SMYD3 for oncology, pre-
clinical
4. EZH2, hit-to-lead
5. KMT target 4 for oncology,
hit-to-lead
6. KMT target 5 for oncology,
hit ID
1. Hormone dependent tumors such as endometrial, breast,
and prostate; GnRH inhibitors and accompanying assay
2. Hormone dependent diseases such as endometriosis,
prostate cancer, BPH, and PCOS; kisspeptin and GPR54
inhibitors, completed in mice, rat and sheep models
3. Leiomyosarcoma, pancreatic cancer, and
hepatocarcinoma; anti-CD146 antibody called AA98
Keywords: immuno-oncology, immunology, oncology,
antibodies, neoplasm, signaling molecule modulator,
Millipore kinase panel
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent medical
research charity committed to innovation in multiple fields.
1. Gene-Directed Enzyme Prodrug Therapy, for treatment of
lung, colorectal, head and neck tumors, as well as hepatoma
(pre-clinical, Phase I to begin in 2016)
2. LOX inhibitors, against tumor metastasis (lead opt.)
Assets
1. Unnamed bicyclic oncologic agents, pre-clinical
2. Unnamed bicyclic ophthalmic agents, pre-clinical
3. Research collaboration opportunities to apply proprietary
platform to targets from partners
Keywords: immuno-oncology, immunology, benign prostatic
hyperplasia, poly-cystic ovarian syndrome, breast cancer,
antibodies, pancreatic cancer, hepatocarcinoma
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent medical
research charity committed to innovation in multiple fields.
Contact: Mrs. Arvind
Hundal, President and Chief
Business Officer
Description: R&D stage company backed by Atlas Ventures
and Novartis Venture funding, among others, exploring the
therapeutic possibilities of bicyclic peptides.
Inflammatory and Oncologic
Diseases
Keywords: drug discovery, CRO, COPD, psoriasis,
oncology, cancer, epigenetics
About
Bicyclic Peptides
Keywords: bicyclic peptides, oncology, ophthalmology,
research collaboration, drug discovery
Name
7. 7
3. TYK2, against MS, RA,
IBD, psoriasis, and T-ALL
(lead opt.)
4. VEGFR-3, against lung,
gastric, and prostate cancers
(lead opt.)
Contact: Dr. John Reader,
CSO
Description: Drug discovery company that produces
targeted small molecule therapeutics focusing on cancer and
auto-immune disease for early stage out-licensing.
1. Chk-1, against pancreatic,
lung, neuroblastoma, and
AML cancers (pre-clinical)
2. Aurora+FLT3, against
AML and ALL (pre-clinical)
Oncology & Autoimmune
Diseases
Keywords: oncology, lung cancer, neuroblastoma, acute
myeloid leukemia (AML), pancreatic cancer, psoriasis,
rheumatoid arithritis (RA), multiple sclerosis (MS)
Keywords: enzyme inhibition, PI3K pathway, breast cancer,
ovarian cancer, targeted synergy, checkpoint kinase
Contact: Mr. Bob Boyle,
CEO
Description: Dedicated to the discovery of new cancer
treatments "void of... systemic toxicities". Interested in
licensing / collaborating at pre-clinical IND phase.
Name
Oncology 1. S6K1, selective oral inhibitor for breast and ovarian
cancers, pre-clinical, seeking partnership
2. Targeted Synergy (TS), proprietary novel approach for the
treatment of solid tumors, pre-clinical
About Assets
8. 8
1. Anti-KSR monoclonal antibodies
2. Monoclonal antibodies against EGFR, thorough preclinical
characterization for all, one has completed Phase 1B trials
3. Monoclonal antibodies against Cerb-B2, extensive
preclinical evaluation completed
Keywords: bispecific antibodies, immuno-oncology,
inflammatory disease, cytokines, asset-centric vehicle
companies
1. Bispecific antibody programs in immuno-oncology and anti-
inflammatory indications
2. Modular Antibody Technology platform for strategic
collaborations on bispecific antibodies and Fc-based formats
Contact: Dr. Jane Dancer,
Chief Business Officer
Antibody Therapeutics
Opportunities
Keywords: rat monoclonal antibodies, Her2, Neu, KSR,
EGFR, Cerb-B2
Contact: Dr. Toby
Richardson, Associate
Director of BD
Description: A University of London and Royal Marsden
hospital affiliated research charity which ranks in the top four
institutes for cancer research worldwide.
About
T Cell Receptor-Based
Therapies
Keywords: ImmTAC, T cell receptor, immunology, oncology,
HLA targets, malignant cutaneous melanoma, ocular
melanoma, glioblastoma
Contact: Dr. Eliot Forster,
Chief Executive Officer
Description: Clinical-stage company focused on innovative
therapies called ImmTACs, based on its proprietary T cell
receptor technology.
Contact: Dr. Paul Kerr,
Managing Director
1. IMCgp100, completed
Phase II for malignant
cutaneous and ocular
melanoma; to begin Phase I
for glioblastoma
Assets
Description: Clinical-stage company focused on the
development of bispecific antibodies for the treatment of
immuno-oncologic and inflammatory diseases.
Fusion Antibodies
2. Undisclosed, pre-clinical
3. Undisclosed, pre-clinical
4. Undisclosed, pre-clinical
5. Undisclosed, pre-clinical
Name
Keywords: immuno-oncology, monoclonal antibodies,
colorectal cancer, breast cancer, lung cancer, prostate
cancer, glioblastoma
2. Fsn1006, a dual specific
IgG1 monoclonal antibody
which binds AREG and HB-
EGF, against colon, breast,
lung and other cancers (pre-
clinical)
Multispecific Antibodies:
KAR-T™ and iCheck™
Tribody™ Agents
Keywords: triple negative breast cancer, colorectal cancer,
malignant mesothelioma, NSCLC, 5T4, CSPG4, HER2,
PLAC1, ROR1, T cell therapy, immune-checkpoints
Contact: Dr. Pedro de
Noronha Pissarra, CEO
Description: Immuno-oncology company developing
multispecific T-cell engagers and immune-modulators which
locally counter potential blocking signals on T and NK cells.
1. Fsn0503h, an anti-
Cathepsin S antibody,
against colorectal, breast,
prostate, glioblastoma and
other cancers (pre-clinical as
monotherapy and in
combination)
Bispecific Antibodies
1. Tb535, pan-cancer T-cell
engager for 5T4 expressing
tumors, pre-clinical
2. Tb434, pan-cancer T-cell
engager against Triple
Negative Breast Cancer, pre-
clinical
3. Tb232, novel anti-HER2 T-
cell engager for mutated and
standard-of-care resistant
metastatic breast cancers,
pre-clinical
4. Various early-stage
programs for partnership
Description: Antibody humanization company with a
preclinical-stage pipeline of antibodies through its Fusion
Therapeutics division.
9. 9
Assets
Description: Clinical-stage company focused on oncolytic
mediated immunotherapy in a number of cancer indications
and advanced preclinical next generation platform of armed,
targeted and immune modulatory oncolytic-immuno agents.
Oncolytic Immunotherapy
Keywords: oncolytic virus, immunotherapy, cancer vaccine,
virotherapy, anti-tumor immune response, mesothelioma,
glioma, autologous cell therapy
Name About
1. KY1005, Anti-OX40L, for
immunology, pre-clinical
2. KY1006, Anti-LIGHT, for
immunology, pre-clinical
3. KY1003, Anti-PD-L1, for
immuno-oncology, pre-
clinical
4. Eleven other discovery-
stage assets for oncology,
anemia, chronic pain, ebola
and others
5. Partnerships employing
the proprietary Kymouse™
drug discovery platform
Keywords: monoclonal antibodies, immunology, oncology,
drug discovery, mouse models, anemia, chronic pain,
dyslipidemia, infectious diseases, ebola
Contact: Dr. Steve Dowd,
Director, Business
Development
Description: Preclinical-stage company focusing on
development of monoclonal antibody drugs in immuno-
oncology, immunology, and opportunistic spaces.
Metzincin Protease
Inhibitory Antibodies
Keywords: ophthalmology, oncology, adenocarcinoma,
prostate and breast cancers, monoclonal antibodies, target
identification platform
Oncolytic Vaccines
Keywords: oncolytic vaccines, antibodies, tumor-targeted
delivery, anti-catabolics, epithelial cancers, sarcopenia
Monoclonal Antibodies
1. Unnamed ADAM-15 monoclonal antibody inhibitor for anti-
angiogenesis & anti-cancer therapy, pre-clinical
2. AbIMP® platform: enabling antibody platform for selective
inhibition of target metzincin proteases, proof-of-concept
Contact: Dr. Salman
Rahman, Co-Founder &
CEO
Description: Preclinical-stage company focused on the
development of metzincin protease inhibitory antibodies as
anti-angiogenic and cancer therapies.
1. SEPREHVIR® investigational cancer-destroying oncolytic
immunotherapy using modified HSV-1
2. SEPREHVEC® proprietary virus engineering system that
allows rapid generation of novel oncolytic viruses with added
arming, targeting or immune modulation.
Contact: Lynne Braidwood,
Product Development
Specialist
1. Espindolol, anti-catabolic for Cancer Cachexia (end phase
II), Sarcopenia (pre-clinical)
2. AbEnAd, "antibody armed oncolytic platform", pre-clinical
3. Enadenotucirev, oncolytic vaccine for colorectal, ovarian,
invasive bladder, renal cell carcinoma, and non-small cell
lung cancers (all phase I).
Contact: Dr. Priya Mande,
Chief Operating Officer
Description: Oxford-based dev-stage biotech company
focused on cancer therapeutics; proprietary platform of
tumor-targeted delivery with oncolytic vaccines.
10. 10
1. "Oxygen" for STEMI,
stroke and kidney transplant
(pre-clinical)
2. "Metabolic" for type II
diabetes and obesity (pre-
clinical)
3. "Life" for melanoma and
solid tumors (pre-clinical)
4. "Growth" for placental
insufficiency, pre-eclampsia
and pre-term labour (pre-
clinical)
5. "Flow" for biodegradable
stent and stem cell therapy
(pre-clinical)
Smart nebulsation technologies:
AKITA® Jet, AKITA2 , FOX
Dry Powder Inhaler Device technologies:
GyroHaler® , Lever-operated multi-dose inhaler (LOMI),
Single Unit Dose DPI
Formulation technologies:
PowderHale®, ParticleMAX® Spray Drying
1. Yaq-001, oral, engineered carbon-powder, against
cirrhosis and fatty liver disease, (pre-clinical)
2. Yaq-002, a liver dialysis device, (pre-clinical)
Multi-Disease
Contact: Dr. Peter Hirst,
Director, Corporate
Development
Airways Diseases
Keywords: airways disease, formulation, inhalation,
pediatric asthma, adult asthma, chronic cough, severe
inflammatory airways disease
About
Keywords: hepatology, liver failure, liver dialysis device,
engineered carbon, cirrhosis, fatty liver disease
Contact: Mr. Daniel Green,
CEO
Contact: Dr. David
Campbell, CEO
Description: Preclinical-stage company with multiple
development programs based on five technologies with
differing foci, each with a lead scientist from UCL.
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent medical
research charity committed to innovation in multiple fields.
Liver Therapies
Respiratory
1. IL17BR Humanized
Antibody
2. COPD and CF; novel
biologic with enormous
therapeutic potential
3. Tuberculosis; rapid ex
vivo diagnostic
Cardiovascular
1. Myocardial Infarction;
small molecule for
cardioprotection following
ischemia-reperfusion injury
during heart attack
Name Assets
Description: Develops pharmaceutical therapies for airways
diseases. Eight marketed products currently. Out-licenses
formulation and inhalation technologies as well.
Cardiovascular and
Respiratory Opportunites
Keywords: heart attack (MI), COPD, cystic fibrosis (CF),
tuberculosis (TB), diagnostic antibodies, protein, peptide,
pulmonary fibrosis, type-2 immune response, humanized
antibody, inflammatory response
Keywords: vascular disease, stroke, kidney transplant,
heart disease, prenatal diseases, oncology, skin cancer,
diabetes, obesity, metabolic disease
Description: Preclinical-stage company focused on
developing a family of liver disease diagnostics and
treatments.
11. 11
1. NM0127 'METDoloron', for mod to severe pain, Phase I
2. NM0133 'METSporine', for ocular conditions, Phase I
3. NM0147 'METAmphizon', for leishmaniasis, Phase I
4. NM0141 'METEnkalon', for undisclosed, pre-clinical
5. NM0151, MET, for undisclosed, pre-clinical
6-7. NM0132 and NM0134, for undisclosed ocular, pre-clin
8. NM0161, 'METXytocin', for undisclosed, pre-clinical
Contact: Prof. Andreas
Schatzlein, CEO
MET Nanoparticles
Keywords: nanoparticles, nanomedicine, nanotechnology,
molecular envelope, pain, ocular therapy, ophthalmology,
leishmaniasis
Description: Primary objective of increasing the availability
of authorized specialty medicines. Therakind has already
brought two pediatric products (one of which had the first
PUMA approved) to market and has an extensive pipeline.
Assets
Description: Clinical stage company developing easily
administered therapeutics and vaccines using solid dose
formulation and proprietary injection device.
1. Glide SDI® (Solid Dose
Injector), pre-clinical
2. Octreotide SDI® , phase I
in H2 2015
3. Teriparatide SDI®, phase
I in H2 2016
Respiratory Delivery and
Consumables
Keywords: drug delivery, respiratory, inhalers, injectables,
device manufacturing, device licensing
Delivery Via Gold
Nanoparticles (GNPs)
Keywords: nanotech, gold nanoparticles, rare cancers,
diabetes, neurology, ophthalmology, glioblastoma, brain
cancer, ovarian cancer, liver cancer, pancreatic cancer
Contact: Dr. Tim Sparey,
Chief Business Officer
Description: Clinical-stage nanomedicine company focused
on the development of multiple, high-value, targeted
therapies for diseases with unmet medical need.
1. Syrina, range of injectors from assisted syringes to auto-
injectors, VapourSoft technology, for out-licensing
2. Lapas, market-ready bolus injection device with
VapourSoft technology, disposable, for out-licensing
3. Lila, pre-filled syringe technology which allows two-drug
mixing, for out-licensing
Patient-Centric Devices and
Diagnostics
Keywords: self-administration, peptides, injectables, solid
dose, vaccines, influenza, anthrax, needle-free, patient-
centric, osteoporosis, acromegaly
Contact: Dr. Tony Mills,
Director of Business
Development
Description: Clinical-stage company focused on the use of
proprietary Molecular Envelope Technology (MET)
nanoparticles in therapies with enhanced bioavailability.
1. GNP Insulin, Phase II
2. GLP-1 / Q-Exenatide,
Phase I
3. GLP-1 / Insultin
combination, pre-clinical
4. For glioblastoma, pre-
clinical
5. Q-Ocreotide, pre-clinical
6. For ovarian cancer, med
chem
7. For liver cancer, med
chem
8. For pancreas cancer, med
chem
Contact: Dr. Susan Conroy,
Chief Executive Officer
1. Reformulation of cytotoxic drug for children and adults -
EU Marketing Authorisation application
2. Undisclosed device for severe hypoglycemia
3. Undisclosed, novel, reusable, intranasal drug delivery
device, pre-clinical.
Name About
Specialty Drug Delivery
Keywords: specialty, pediatric, orphan, geriatric, chronic,
drug delivery, severe hypoglycemia, diabetes, intranasal
device, neonate, cytotoxic, adherance, oral liquid, buccal,
GCP compliance, oncology, chemotherapy, immunology, PIP
4. Exenatide SDI®, proof-of
concept PK H2 2015
5. Anthrax vaccine,
partnered with Pfenex Inc,
preclinical
6. rHA influenza vaccine,
preclinical feasibility
Contact: Mr. Steven
Kaufman, Global Business
Development Lead
Description: A Consort Medical company and a leading
global supplier of drug delivery devices for injectable and
inhaled products, with a focus on the respiratory market.
12. 12
Keywords: epigenetics, biomarkers and diagnostics,
prognostics, sequencing, regulation tool, de novo
methylation, oncology, preventative medicine
1. Crohn's Disease; epigenetic diagnostic test
2. Renal Cell Carcinoma (RCC); four biomarkers for
prognosis and therapeutic outcome
3. Familial Hyperlipidemia (FH); next-generation sequencing
diagnostic tool
4. Methylation regulation tool, for analysis of genes subject to
epigenetic control through de novo methylation
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent medical
research charity committed to innovation in multiple fields.
Gene-Based Medicine
Keywords: gene therapy, cell therapy, lentiviral vectors, age-
related macular degeneration, chronic glaucoma,
Parkinson's disease, oncology, cancer vaccines
Contact: Mr. Peter Nolan,
Chief Business Officer
Description: Clinical-stage company focused on the
development of gene and cell therapies for ophthalmic, CNS,
and oncologic diseases.
Tumor Apoptosis Enhancers
(TAEs)
Keywords: tumor apoptosis enhancers, oncology, nano-
technology, cancer
Contact: Mr. Alan Walker,
CEO
About
1. Atu027, against pancreatic cancer, Phase II
2. Atu027, against head and neck cancer, Phase I
3. Atu111, against lung indications, pre-clinical
4. Unnamed, against pulmonary hypertension, discovery-
stage
5. Pre-clinical microRNA and messenger RNA programs
Gene Silencing
RNA-based Therapeutics
Keywords: genetic medicine, pancreatic cancer, head and
neck cancer, lung disease, pulmonary hypertension, RNA
interference, gene silencing, messenger RNA, RNAi, mRNA
Description: Clinical-stage company developing cancer
therapies and associated biomarkers, with sub-focuses in
neurology and inflammatory disease.
Genetics and Genomics
Opportunities
Contact: Dr. Satu Vainikka,
CEO
Contact: Dr. Lars Karlsson,
Head of Research &
Development
Description: Clinical-stage company which utilizes RNA
interference (RNAi) and mRNA technology to develop
therapies which 'silence' disease-causing gene expression.
Description: Clinical-stage company focused on the
development of Tumor Apoptosis Enhancers to treat cancer,
making chemotherapy many times more effective.
Assets
1. ECP-102, a TAE for an undisclosed cancer indication
(Phase I)
1. LentiVector® gene therapy platform technology
2. OXB-102/ProSavin® for Parkinson’s disease Phase I/II
3. TroVax® cancer vaccine for solid tumours, Phase II
4. RetinoStat® for “wet” AMD, Phase II ready
5. EncorStat® for corneal graft rejection, Phase I/IIa prep
6. Pre-clinical candidates: CAR-T 5T4, MoNuDin®, cystic
fibrosis, orphan ophthalmology indications
1. VAL101 GeneICE Bcl-2 inhibitor, against prostate,
ovarian, and pancreatic cancers, pre-clinical
2. VAL201, against prostate cancer (with potential in breast
and ovarian cancers, endometriosis), Phase I
3. VAL401, against lung cancer, pre-clinical
4. NAV3 biomarker, for cancer screening, Phase I
Name
Keywords: genetic medicine, oncology, GeneICE, Bcl-2
inhibition, prostate cancer, breast cancer, ovarian cancer,
endometriosis, cancer screening, lung cancer
13. 13
Virus-Like Particle Vaccines
Keywords: vaccines, virology, infectious disease, virus-like
particles, influenza, malaria, hepatitis, burkholderia, FMDV,
CMV, cancer, Tandem Core™
Contact: Dr. Alex Ramirez,
Lead Immunologist
Description: Preclinical-stage company focused on the
development of a broad spectrum of vaccines delivered as
proprietary virus-like particles (VLPs).
Name About Assets
Head Lice
Keywords: head lice, aphids, greenfly, red mites, cat ear
mites
RSV Keywords: antiviral, RSV, respirator syncytial virus
1. RSVF, for RSV, at point-of-care candidate selection
2. RSVrep, for RSV, in pre-clinical development
Contact: Dr. Khatereh
Ahmadi, CEO and Founder
Description: re:VIRAL is an emerging, preclinical-stage,
Wellcome Trust funded biopharma company focused on its
first-in-class antivirals against RSV.
Anti-Infectives
1. MDR Gram (+), lead opt
2. MDR Gram (-), H2L
3. Hepatitis B, H2L
4. Influenza, H2L
5. Novel bacterial targets,
discovery
Anti-Infectives and Oncology
Keywords: small molecules, anti-infectives, oncology,
antibacterial, antiviral, MDR, influenza vaccine, hepatitis B,
tumors, cancer inhibitors, Gram positive and negative
Contact: Dr. Sarah Maxfield,
Head of Business
Development
Description: Preclinical-stage drug discovery company
focused on the development of small molecule therapeutics,
particularly in oncology and infectious disease.
1. KindaPed™, a market-ready anti-head lice treatment,
seeking partnerships for manufacturing and marketing in the
US and China. (Also shows promise in crop treatment for
aphids and greenfly, as well as 80-90% efficacy against red
mites in chickens and cat ear mites).Contact: Mr. Alan Walker,
CEO
Vaccine for...
1. FMDV, pre-clinical
2. CMV, pre-clinical
3. Cancers, discovery &
development stage
Oncology (inhibitor of...)
1. Smoothened, IND ready
2. cFMS, lead opt
3. BTK, lead opt
4. Porcupine, lead opt
5. Other tumor/ immunology
targets, H2L / discovery
Infectious Disease
Opportunities
Keywords: vaccines, diagnostics, mouse models, new class
of antivirals, HIV-1, asthma, ulcerative colitis (UC), hepatitis
C (HCV), tuberculosis (TB)
1. Tuberculosis; rapid ex vivo diagnostic
2. HIV-1; a universal HIV-1 vaccine called HIVcon
3. Asthma and Ulcerative Colitis; antibody against IL-25 and
type 2 immune responses, humanized
4. Hepatitis C; a humanized, broadly neutralizing antibody
5. Disovery of a new class of antivirals, for exploitation
6. Junbo, a mouse model with OM for antibiotic research
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent medical
research charity committed to innovation in multiple fields.
Vaccine for...
1. Influenza, pre-clinical
2. Malaria, pre-clinical
3. Hepatitis, pre-clinical
4. Burkholderia, pre-clinical
Description: Development-stage company focused on its
KindaPed™ anti-head lice treatment. Recently demonstrated
efficacy against mites in chickens and cats.
14. 14
Contact: Dr. Barbara
Domayne-Hayman, Chief
Business Officer
Description: Clinical stage company focused on
therapeutics for hearing disorders, as well as a candidate for
schizophrenia.
Psychiatric, Behavioral and
CNS Therapeutics
Keywords: epilepsy, bipolar disease, depression, insomnia,
addiction, pain, psychosis, Tourette's, CNS, Parkinson's,
sexual dysfunction, aggression, anxiety
1. For Tourette's,
Parkinson's, EPS, research
2. For sexual dysfunction,
research
3. For aggression, research
4. For anxiety, research
1. AUT00063, in Phase IIa for age-related hearing loss in the
US and in Phase IIa for tinnitus in the UK
2. AUT00206, for schizophrenia, pre-clinical
Name About Assets
Contact: Mr. Russ
Pendleton, Managing
Director
Description: Clinical-stage company focused on the
development of drugs for psychiatric and psychotic
disorders, as well as central nervous system disease
Hearing Disorders Keywords: age related hearing loss, tinnitus, schizophrenia
1. For epilepsy, bipolar &
depression, "launched"
2. For insomnia, "launched"
3. For addiction & pain, "pre-
launch"
4. For psychosis relapse,
Phase II
1. Spinal cord injury; Nogo inhibitor to increase regeneration
2. Multiple sclerosis; small molecule decreases progression
3. Parkinson's; assay to screen for LRRK2 inhibitors
4. Parkinson's; surgical technology for unambiguous
identification of neural centers
5. Migraine; drug discovery project for TRESK activators
6. Pain; drug discovery project for TrkA target
Neurobiology Opportunities
Keywords: neurology, surgical tools and technology, spinal
cord injury, MS, multiple sclerosis, Parkinson's disease,
migraine, pain
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent charity
committed to preclinical-stage innovation in multiple fields.
15. 15
Medical Devices
Opportunities
Keywords: rapid and accurate slicing of tissue samples, co-
alignment, tissue imaging, tissue arrays, high sample
density, cervix imaging
Contact: Dr. Toby
Richardson, Associate
Director of BD
Description: A University of London and Royal Marsden
hospital affiliated research charity which ranks in the top four
institutes for cancer research worldwide.
Device and Software
Opportunities
Keywords: medical devices, advanced wound healing,
regenerative medicine, product packaging, imaging, TEM,
OPT, HTS, graphene delivery
1. Optical projection tomography (OPT) 3D microscopy for
research and diagnostics
2. Novel graphene support films for biological molecules
3. Flywheel, a modular platform for live HTS imaging
4. GMCSH-PGE, for wound healing, topical or in dressings
5. Oxygen sensors for packaging (shelf-life monitor)
6. TEM imaging quality improvement technology
Contact: Dr. Michael
Dalrymple, Director of
Business Development
Description: MRC Technology is the tech transfer arm of
the Medical Research Council, an independent charity
committed to preclinical-stage innovation in multiple fields.
Software Opportunities
Keywords: image analysis, dosimetry, radionuclide therapy,
MIPs, MR contrast capable kinetics, MRI, kinetic volume,
tissue movement artifacts, MRI distortion correction
Contact: Dr. Toby
Richardson, Associate
Director of BD
Description: A University of London and Royal Marsden
hospital affiliated research charity which ranks in the top four
institutes for cancer research worldwide.
Tissue Regeneration
Devices
Keywords: tissue regeneration, orthopedic matrices, cell
therapy, drug delivery
Contact: Dr. Robin Quirk,
Executive Director
Description: Preclinical-stage company focused on the
development of their proprietary TAOS injectable matrix
technology, and several potential applications thereof.
1. Dosimetry for radionuclide
treatment, currently used to
support clinical studies
2. 4D Orthogonal Display
Tool, evaluation ongoing
3. MRI Distortion Correction
algorithms, evaluation
ongoing
4. 3D kinetic volume
rendering tool for MRI,
evaluation on-going
1. TAOS Osteoinductive Therapeutic, for orthopedic bone
and joint fusion indications, pre-clinical
2. TAOS Osteoconductive Void Filler, for grafting
procedures, pre-clinical
3. Utilization of TAOS technology in external development
programmes, including localised delivery and sustained
release of small drug molecules, biologics and cell therapies
Name About Assets
1. RDC5, for osteoporosis
and neurodegenerative
diseases, Phase II ready
2. RDC5, for neuro-
degenerative diseases,
preclinical
3. ChronoscreenTM, a
proprietary chronological
screen. Screening
partnerships underway with
major Pharma.
1. Device for tissue processing, prototypes have been sold to
academic researchers
2. Endocovitary coil for 3T-MRI, (POC, clinical ongoing)
Anti-Aging Therapies
Keywords: cellular chronological lifespan regulation, anti-
aging, ALS, Parkinson's, Alzheimer's, osteoporosis, age-
related diseases, oncology
Contact: Dr. Huw Jones,
CEO
Description: Clinical-stage company focused on the
development of repositioned FDA/EMA approved drugs and
proprietary candidates which regulate cellular lifespan
16. 16
Microbial-Derived
Therapeutics
Keywords: drug discovery, R&D collaboration, natural
products, small molecules, mitochondria-related diseases
1. TarGET (Targeted Genome Evolution Technologies)
platform
2. Soil bacteria compound libraries - multi-million bacterial
species libraries from the soil with full access to all novel
small molecules genetically possible
Contact: Ms. Ipshita
Mandal, Business
Development Officer
Description: Fully exploring nature's diversity for novel small
molecules, with multi-TA target screening based on ultra-
rapid cell-based phenotype studies.
Name About Assets
